Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats

Indian Journal of Pharmacology

Volumn 44, Issue 6, 2012, Pages 774-779

  Zaitone, Sawsan A ^a   Abo Elmatty, Dina M ^a   Elshazly, Shimaa M ^b  

^a SUEZ CANAL UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

Dopamine; Parkinson's disease; piracetam; rotenone; vinpocetine

Indexed keywords

DOPAMINE; GLUTATHIONE; MALONALDEHYDE; PIRACETAM; ROTENONE; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEGENERATION; CONTROLLED STUDY; CORPUS STRIATUM; HISTOPATHOLOGY; LOCOMOTION; MALE; MOTOR PERFORMANCE; NERVE CELL; NEUROPROTECTION; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; RAT; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; DRUG THERAPY, COMBINATION; GLUTATHIONE; MALE; MALONDIALDEHYDE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PIRACETAM; RATS; ROTENONE; TUMOR NECROSIS FACTOR-ALPHA; VINCA ALKALOIDS;

EID: 84870025323     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.103300     Document Type: Article

References (29)

1. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2006;70:373-81.
2. Mogi M, Kondo T, Mizuno Y, Nagatsu T. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci Lett 2007;1:94-7.
3. Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD. Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 2006;2:149-88.
4. Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav Immun 2007;21:47-59.
5. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J 2006;8:E606-21.
6. Giurgea CE. The nootropic concept and its prospective implications. Drug Dev Res 1982;2:441-6.
7. Ciarlone AE, Juras MS. Lidocaine and procaine alter rat brain amines. J Dent Res 1981;60:1886-90.
8. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: From basic science to novel clinical applications to CNS disorders. Drugs 2010;3:287-312.
9. Valikovics A. [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz 2007;60:301-10.
10. Thiffault C, Langston JW, Di Monte DA. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 2000;885:283-8.
11. Rao NV, Pujar B, Nimbal SK, Shantakumar SM, Satyanarayana S. Nootropic activity of tuber extract of Pueraria tuberosa (Roxb). Indian J Exp Biol 2008;8:591-8.
12. Abdel Salam OM, Oraby FH, Hassan NS. Vinpocetine ameliorates acute hepatic damage caused by administration of carbon tetrachloride in rats. Acta Biol Hung 2007;4:411-9.
13. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: Possible relevance to parkinsonism. Behav Brain Res 2004;148:47-54.
14. Conceição IM, Frussa-Filho R. Effects of a single administration of buspirone on catalepsy, yawning and stereotypy in rats. Braz J Med Biol Res 1993;26:71-4.
15. Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 2004;17:123-30.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
17. Griffith OW. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 1980;106:207-12.
18. Mizutani A, Okajima K, Uchiba M, Isobe H, Harada N, Mizutani S, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003;101:3029-36.
19. Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, et al. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 2004;7:726-35.
20. Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 2006;27:6.
21. Sindhu KM, Saravanan KS, Mohanakumar KP. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005;1051:25-34.
22. Abd-El Gawad HM, Abdallah DM, El-Abhar HS. Rotenone-induced Parkinson's like disease: modulating role of coenzyme Q10. J Biol Sci 2004;4:568-74.
23. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004;10 Suppl 1:S3-7.
24. Campbell IL. Cytokine-mediated inflammation and signaling in the intact nervous system. Prog Brain Res 2001;132:481-98.
25. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: Role of TNF-alpha. FASEB J 2006;20:670-82.
26. Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WE. Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol 2006;147:199-208.
27. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 2009;620:49-56.
28. Al-Bahrani A, Taha S, Shaath H, Bakhiet M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res 2007;4:31-7.
29. Feher G, Koltai K, Kesmarky G, Horvath B, Toth K, Komoly S, et al. Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009;16:111-7.